Therapeutic Ocular HSV Vaccine in HLA Transgenic Rabbits
Therapeutic Ocular HSV Vaccine in HLA Transgenic Rabbits
批准号:
8523888
负责人:
Lbachir BenMohamed
金额:
$34.88万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-09-01 至 2015-08-31
关键词:
AdultAfferent NeuronsAnimal ModelBlindnessCD4 Positive T LymphocytesCD8B1 geneCervicalComplexCorneaDNA VirusesDeveloped CountriesDevelopmentDiseaseEpitopesEvaluationEyeEye diseasesGlycoproteinsHLA AntigensHerpes Simplex Virus VaccinesHerpesvirus 1Herpetic KeratitisHumanImmuneImmune responseImmunityImmunizationImmunotherapeutic agentIn VitroIndividualInfectionInterferon Type IIKeratitisKnowledgeLaboratoriesLatent VirusLeadMemoryModelingMusNational Eye InstituteNational Institute of Allergy and Infectious DiseaseNeedlesOryctolagus cuniculusPeptide VaccinesPopulationRecording of previous eventsRecurrenceResearchRoleSimplexvirusStructure of trigeminal ganglionStudy SectionT cell responseT-LymphocyteT-Lymphocyte EpitopesTechnologyTestingTherapeuticTimeTransgenic OrganismsUnited StatesVaccinationVaccinesVirusVirus Sheddingblindconjunctivacytotoxicgranzyme Bimmunogenicityin vivolymph nodesmicrobial diseasenovelpreventprogramsresponsetherapeutic vaccinevaccine deliveryvaccine efficacyvaccine safety
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Herpes simplex virus 1 (HSV-1) infects the cornea and then establishes latency in sensory neurons of
the trigeminal ganglia (TG). Sporadic spontaneous reactivation of HSV-1 causes shedding of virus in tears
leading to spread of virus to other individuals, and can also cause recurrent Herpes Stromal Keratitis (HSK), a
blinding ocular disease. A major gap in our current knowledge is: "How can we prevent or significantly reduce
virus shedding in tears and HSV-induced ocular disease due to spontaneous reactivation of latent virus in the
TG?" HSV-specific CD8+ T-cells appear to decrease in vitro induced HSV-1 reactivation in explanted mouse
TG. Unfortunately, spontaneous reactivation of HSV-1 in mice is extremely rare so the relevance of these
findings to in vivo HSV-1 spontaneous reactivation cannot be determined in mice. We now have a "humanized"
HLA transgenic rabbit model of ocular HSV-1 that mounts "human-like" CD8 T-cell immune responses (HLA
Tg rabbits). In a Preliminary Study we found that therapeutic immunization of latently infected HLA Tg rabbits
with 3 human CD8 T-cell epitopes from HSV-1 gD decreased spontaneous reactivation 4-fold. This novel
animal model will now allow us for the first time to test the hypothesis that a therapeutic vaccine that induces
appropriate human T-cell responses to HSV-1 can decrease the effects of spontaneous reactivation (virus
shedding in eyes and HSV-induced ocular disease). Our specific Aims include:
(1). Test the hypothesis that therapeutic immunization with HSV-1 human CD8+ T-cell epitopes can
decrease spontaneous reactivation in latently infected HLA Transgenic rabbits. CD4-CD8 lipopeptide vaccines,
bearing different combinations of human CD4+ and CD8+ T cell epitopes from glycoprotein B and D (gB & gD),
will be used to immunize latently infected HLA Tg rabbits. Protection against virus shedding in eyes (due to
spontaneous reactivation) and HSV-induced ocular disease will be determined.
(2). Test the hypothesis that the protective immunity induced by the therapeutic vaccination of HLA
Transgenic rabbits in Aim 1 correlates with the presence of effector and memory CD8+ T-cells in the TG,
conjunctiva, and/or draining lymph nodes. We will assess whether the number/function of HSV- and epitope-
specific CD8+ T cells induced in vivo correlates with protection from spontaneous virus shedding in tears and
ocular disease. We will assess the CD8+ T cell mechanism that correlates with protection.
(3). Test the hypothesis that decreasing CD8+ T cells in latently infected HLA Tg rabbits will abrogate
vaccine efficacy and also increase spontaneous reactivation in unvaccinated rabbits.
These studies will provide important new information regarding the role of CD8+ T cells specific to
human epitopes in immune control of HSV-1 spontaneous reactivation. This may lead to the development of
new paradigms for immunotherapeutic strategies against ocular herpes.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Developing a Multi-epitope Pan-Coronavirus Vaccine
-
批准号:10171239
-
项目类别:
-
资助金额:$74.54万
-
财政年份:2020
-
负责人:Lbachir BenMohamed
-
依托单位:
A Novel Prime/Pull Therapeutic Vaccine Strategy to Prevent Recurrent Genital Herpes
-
批准号:10318146
-
项目类别:
-
资助金额:$61.29万
-
财政年份:2020
-
负责人:Lbachir BenMohamed
-
依托单位:
A Novel Prime/Pull Therapeutic Vaccine Strategy to Prevent Recurrent Genital Herpes
-
批准号:9913971
-
项目类别:
-
资助金额:$69.75万
-
财政年份:2020
-
负责人:Lbachir BenMohamed
-
依托单位:
A Novel Prime/Pull Therapeutic Vaccine Strategy to Prevent Recurrent Genital Herpes
-
批准号:10546435
-
项目类别:
-
资助金额:$61.29万
-
财政年份:2020
-
负责人:Lbachir BenMohamed
-
依托单位:
Developing a Multi-epitope Pan-Coronavirus Vaccine
-
批准号:10231272
-
项目类别:
-
资助金额:$71.8万
-
财政年份:2020
-
负责人:Lbachir BenMohamed
-
依托单位:
Developing a Multi-epitope Pan-Coronavirus Vaccine
-
批准号:10669702
-
项目类别:
-
资助金额:$74.22万
-
财政年份:2020
-
负责人:Lbachir BenMohamed
-
依托单位:
A Novel Prime/Pull Therapeutic Vaccine Strategy to Prevent Recurrent Genital Herpes
-
批准号:10083701
-
项目类别:
-
资助金额:$68.49万
-
财政年份:2020
-
负责人:Lbachir BenMohamed
-
依托单位:
Developing a Multi-epitope Pan-Coronavirus Vaccine
-
批准号:10454975
-
项目类别:
-
资助金额:$75.69万
-
财政年份:2020
-
负责人:Lbachir BenMohamed
-
依托单位:
Mucosal Chemokines and CD8+ T Cell Immunity to Genital Herpes
-
批准号:10223136
-
项目类别:
-
资助金额:$60.33万
-
财政年份:2019
-
负责人:Lbachir BenMohamed
-
依托单位:
Mucosal Chemokines and CD8+ T Cell Immunity to Genital Herpes
-
批准号:10450154
-
项目类别:
-
资助金额:$59.97万
-
财政年份:2019
-
负责人:Lbachir BenMohamed
-
依托单位:
Mechanisms of CD8+ T Cell Dynamics in Recurrent Ocular Herpetic Disease
-
批准号:9752627
-
项目类别:
-
资助金额:$37.5万
-
财政年份:2016
-
负责人:Lbachir BenMohamed
-
依托单位:
Mechanisms of CD8+ T Cell Dynamics in Recurrent Ocular Herpetic Disease
-
批准号:9183816
-
项目类别:
-
资助金额:$38.81万
-
财政年份:2016
-
负责人:Lbachir BenMohamed
-
依托单位:
LAT-HVEM Interactions Effect HSV-1 Latency/Reactivation
-
批准号:9084450
-
项目类别:
-
资助金额:$19.31万
-
财政年份:2015
-
负责人:Lbachir BenMohamed
-
依托单位:
Blockade of T-cell Co-Inhibitory Pathways & Immunotherapy to Prevent Ocular Herpe
-
批准号:9121574
-
项目类别:
-
资助金额:$38.63万
-
财政年份:2014
-
负责人:Lbachir BenMohamed
-
依托单位:
Therapeutic Ocular HSV Vaccine in HLA Transgenic Rabbits
-
批准号:7986401
-
项目类别:
-
资助金额:$19.13万
-
财政年份:2010
-
负责人:Lbachir BenMohamed
-
依托单位:
Therapeutic Ocular HSV Vaccine in HLA Transgenic Rabbits
-
批准号:8327246
-
项目类别:
-
资助金额:$36.72万
-
财政年份:2010
-
负责人:Lbachir BenMohamed
-
依托单位:
Therapeutic Ocular HSV Vaccine in HLA Transgenic Rabbits
-
批准号:9112499
-
项目类别:
-
资助金额:$46.35万
-
财政年份:2010
-
负责人:Lbachir BenMohamed
-
依托单位:
Therapeutic Ocular HSV Vaccine in HLA Transgenic Rabbits
-
批准号:8128628
-
项目类别:
-
资助金额:$36.72万
-
财政年份:2010
-
负责人:Lbachir BenMohamed
-
依托单位:
Therapeutic Ocular HSV Vaccine in HLA Transgenic Rabbits
-
批准号:8710229
-
项目类别:
-
资助金额:$35.99万
-
财政年份:2010
-
负责人:Lbachir BenMohamed
-
依托单位:
Developing A Tissue-Targeted Ocular HSV Therapeutic Vaccine
-
批准号:10600045
-
项目类别:
-
资助金额:$41.0万
-
财政年份:2010
-
负责人:Lbachir BenMohamed
-
依托单位:
海外基金